Opinion
NOS. Misc. No. 99-197(TFH), (M.D.L. No. 1285), Civil Action No. 99-CV-3226 (C.D. Ill.), Docket No. 99-2683 (TFH), Civil Action No. 99-5145 (W.D. Ark.), Docket No. 99-2681 (TFH), Civil Action No. 2:99.CV-0152-WCO (N.D. Ga.), Docket No. 99-2682 (TFH), Civil Action No. IP99-1941 C-T/G (S.D. Ind.), Docket No. 00-234 (TFH), Civil Action No. 2-99CV-288-J (N.D. Tex.), Docket No. 99-2684 (TFH), Civil Action No. 5:99CV00070 (W.D.Va.), Docket No. 99-2685 (TFH), Civil Action No. 99-CV-1780 (D. Minn.), Docket No. 99-1780 (TFH), Civil Action No. 99-CV-384 (D. Minn.), Docket No. 99-1526 (TFH).
December 20, 2002
All of the remaining parties to the above-captioned actions, specifically plaintiffs and Hoffman LaRoche Inc., Roche Vitamins Inc. and F. Hoffman LaRoche Ltd., have informed the Court that a confidential settlement agreement has been reached in principle and that the parties jointly wish to have the settlement approved and authorized by the Court.
Seeing no reason not to approve the settlement, on the consent of counsel to all parties, it is hereby ORDERED that the Court approves the settlement, including the establishment thereunder of a qualified settlement fund pursuant to Internal Revenue Code Section 468B and the Treasury Regulations promulgated thereunder, and retains continuing jurisdiction as to any issue that may arise in connection with the terms of the settlement, including any issue that may arise in connection with the formation and/or administration of the qualified settlement fund. Upon full execution of the settlement agreement, the parties are directed to proceed with implementation of the terms thereof, including the payment into the qualified settlement fund of monies due pursuant to the settlement agreement. Counsel for plaintiffs may, without further order of this Court, direct payment from the qualified settlement fund as contemplated by the settlement agreement.